Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

By T. Hideshima, D. Chauhan, Y. Shima, N. Raje, F. Davies, Y. Tai, S. Treon, B. Lin, R. Schlossman, P. Richardson and 3 more. Blood, 2000

921 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/f3dcce2191248eb9a66361e6523db98f392c3bbd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. S. Rajkumar
2. J. Adams

In Molecular Biology

1. P. Richardson
2. T. Hideshima
3. J. Adams
4. S. Rajkumar

Citations in the corpus

• The evolution of thalidomide and its IMiD derivatives as anticancer agents (2004, background): “Direct antitumour activity of IMiDs Surprisingly, the IMiDs were found to share another important anticancer property — the ability to directly induce growth arrest and caspase-dependent apoptosis of tumour cell”
• Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets (2007, background): “Lenalidomide, an immunomodulatory drug, has similarly been combined in preclinical studies with several other agents including steroid”